Navigation Links
Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day
Date:3/13/2017

HERCULES, Calif., March 13, 2017 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced several significant strategic priorities, including initiating long term financial guidance, commitment to defining new capital allocation targets, and hosting an annual Investor Day later this year.

Bio-Rad expects to achieve the following financial results for revenue and EBITDA margins:

  • Long-term currency-neutral revenue growth of approximately 3% to 5%
  • Currency-neutral EBITDA margin of greater than 20% by 2020

Bio-Rad will provide further details on its long term revenue growth and profitability goals based on this EBITDA margin target. 

Bio-Rad also plans to define a prudent capital allocation policy focused on maximizing value over the long-term. The Company commits to evaluate leverage levels that will enable Bio-Rad to maintain its strong balance sheet and investment grade credit ratings, while providing flexibility to opportunistically pursue organic growth initiatives and attractive bolt-on acquisitions. Should Bio-Rad identify compelling strategic opportunities that take the Company above this target, management is committed to de-levering back to the target range over time. Given its excess cash position, Bio-Rad intends to move to its target leverage ratio through share repurchases and/or value-creating M&A.

Bio-Rad plans to hold an Investor Day later this year, during which management will discuss the Company's operating performance, organic and inorganic growth priorities and capital allocation strategy.

Norman Schwartz, Bio-Rad Chairman and Chief Executive Officer, commented: "Today marks an important step forward for Bio-Rad. As we cycle through investments designed to enhance our growth and improve our operating efficiency, we are striving to achieve EBITDA margins that will create significant stockholder value over the long-term. We are committed to improving communication with the investor and analyst community as well as actively pursuing additional sell-side coverage."

Reiterates 2017 Financial Outlook

Bio-Rad also reiterated its 2017 financial outlook and continues to anticipate currency neutral revenue growth of approximately 4 percent, and improved profitability with a currency neutral GAAP operating margin of 7 percent for the full year 2017. As previously discussed, guidance includes elevated operating costs due to the implementation of Bio-Rad's ERP system. Revenue and operating margin guidance does not include the impacts of the recent acquisition of RainDance.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "intends," "believes," "expects," "anticipates," "may," "will,"  "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Contacts

Christine Tsingos, Executive Vice President and Chief Financial Officer
Bio-Rad Laboratories, Inc.
510-741-6006
investor_relations@bio-rad.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bio-rad-initiates-long-term-financial-guidance-commits-to-defining-long-term-capital-allocation-targets-and-hosting-an-annual-investor-day-300422383.html


'/>"/>
SOURCE Bio-Rad Laboratories, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. New Products, Price Movements, and Leadership Appointments - Research Report on Waters, Cognex, Fluidigm, Cepheid, and Bio-Rad
2. Global Digital PCR (dPCR) Market 2015-2019 with Bio-Rad Laboratories, Fluidigm, RainDance Technologies & Thermo Fisher Scientific Dominating
3. Global ADME-Toxicology Testing Market 2015-2019 - Advances in Technology with Accelrys, Agilent Technologies, Bio-Rad Laboratories, Promega, Sigma Aldrich & Thermo Fisher Scientific Dominating
4. Global Microfluidics Market Report 2015-2020 Featuring Danaher, Thermo Fisher Scientific, Becton, Dickinson and Co, Agilent Technologies, Bio-Rad Laboratories & PerkinElmer
5. Digital PCR (dPCR) and qPCR Market to 2019 - With Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc and F. Hoffmann-La Roche Ltd Dominating the Market
6. Global In-Vitro Diagnostics Packaging Market 2016-2020 - Leading Vendors are Bio-Rad, Corning, Greiner Bio-One & Narang Medical
7. Global Label-Free Detection Market Value of USD 2.13 Billion by 2020 - Analysis, Trends & Opportunities 2016-2020 - Key Vendors: Attana AB, Bio-Rad & Danaher
8. Research and Markets - Global Chromatography Market 2016-2020 with Agilent Technologies, Bio-Rad Laboratories, Shimadzu & Thermo Fisher Scientific Dominating
9. Research and Markets - General Surgery Devices Market to Reach $17 Billion by 2024, with Abbott Laboratories, Danaher Corporation & Bio-Rad Labs Dominating
10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
11. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 11, 2019 , ... Abilene Christian University (ACU) is offering ... (DNP) degree. The online BSN to DNP program pathway is meant to serve as ... in Nursing (BSN) degree to a Doctor of Nursing Practice degree. , Traditionally, ...
(Date:9/11/2019)... ... September 11, 2019 , ... This event is free and takes place on ... noon to 4 p.m. The Foundation for Senior Services Wellness Expo will feature entertainment ... with experts in a variety of fields. , The mission of the Foundation ...
(Date:9/11/2019)... ... ... HOLLOWAY AMERICA, a leading manufacturer of stainless steel vessels and ... it will showcase its problem-solving vessels and tanks at several shows this fall from ... be at ISPE San Diego’s 27th Life Science Resource Fair at the Del Mar ...
Breaking Medicine Technology:
(Date:9/11/2019)... ... 2019 , ... Women’s Excellence is excited to announce the opening of their ... Suite 103, Royal Oak, MI 48073 in the heart of Royal Oak off Woodward ... services in a contemporary, spa-like atmosphere. We are thrilled to be in a ...
(Date:9/11/2019)... ... September 10, 2019 , ... Episcopal Relief & ... vulnerable communities impacted by Hurricane Dorian. , In partnership with the Episcopal ... of Georgia, and the Episcopal Farmworker Ministry, Episcopal Relief & Development is giving ...
(Date:9/9/2019)... ... September 09, 2019 , ... Sharon, the respected Practice Administrator ... of Dental Office Management (AADOM) Annual Conference. This year, esteemed dentist, Dr. Patrick ... is Sharon’s third nomination in a row. The entire team at Cieplak Dental ...
(Date:9/9/2019)... NEW YORK (PRWEB) , ... ... ... Center of NYC ( https://www.orthodonticscenternyc.com ) located on the Upper East Side ... division to their busy orthodontic practice. The pediatric orthodontic division specializes in ...
(Date:9/8/2019)... ... , ... The reviews from patients of ABM Medical Clinic who have had ... pain free fat loss system, has patients booking their sessions and recommending this procedure ... state of the art technology incorporating radio frequency and heat to rid the fat ...
Breaking Medicine News(10 mins):